JACOB MANDEL to Brain Neoplasms
This is a "connection" page, showing publications JACOB MANDEL has written about Brain Neoplasms.
Connection Strength
4.071
-
External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma. JAMA Oncol. 2023 07 01; 9(7):1006.
Score: 0.413
-
IDH mutation status and the development of venous thromboembolism in astrocytoma patients. J Neurol Sci. 2021 Aug 15; 427:117538.
Score: 0.359
-
Recurrent Papillary Glioneuronal Tumor. World Neurosurg. 2019 Aug; 128:127-130.
Score: 0.310
-
Effect of health disparities on overall survival of patients with glioblastoma. J Neurooncol. 2019 Apr; 142(2):365-374.
Score: 0.304
-
Highlighting the need for reliable clinical trials in glioblastoma. Expert Rev Anticancer Ther. 2018 10; 18(10):1031-1040.
Score: 0.293
-
Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol. 2018 01 10; 20(1):113-122.
Score: 0.283
-
Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis. J Neurol Sci. 2016 Oct 15; 369:51-52.
Score: 0.255
-
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol. 2016 08; 129(1):147-54.
Score: 0.253
-
Intracranial epithelioid hemangioendothelioma causing subacute loss of vision. Neurology. 2015 Aug 25; 85(8):735-6.
Score: 0.240
-
Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. J Neurooncol. 2014 Dec; 120(3):597-605.
Score: 0.224
-
Towards fair decentralized benchmarking of healthcare AI algorithms with the Federated Tumor Segmentation (FeTS) challenge. Nat Commun. 2025 Jul 08; 16(1):6274.
Score: 0.119
-
Discontiguous recurrences of IDH-wildtype glioblastoma share a common origin with the initial tumor and are frequently hypermutated. Acta Neuropathol Commun. 2025 01 16; 13(1):9.
Score: 0.115
-
Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. Oncologist. 2023 04 06; 28(4):327-332.
Score: 0.102
-
Racial and Socioeconomic Disparities in Patients With Meningioma: A Retrospective Cohort Study. Neurosurgery. 2022 01 01; 90(1):114-123.
Score: 0.093
-
Multicentric non-enhancing lesions in glioblastoma: A retrospective study. J Clin Neurosci. 2021 Mar; 85:20-26.
Score: 0.087
-
Exclusion of patients with brain metastases from cancer clinical trials. Neuro Oncol. 2020 04 15; 22(4):577-579.
Score: 0.083
-
Gastrointestinal stromal tumor with intracranial metastasis: case presentation and systematic review of literature. BMC Cancer. 2019 Nov 15; 19(1):1119.
Score: 0.080
-
Treatment strategies for glioblastoma in older patients: age is just a number. J Neurooncol. 2019 Nov; 145(2):357-364.
Score: 0.080
-
Disparities along the glioblastoma clinical trials landscape. Neuro Oncol. 2019 02 14; 21(2):285-286.
Score: 0.076
-
Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. J Neurooncol. 2017 Oct; 135(1):75-81.
Score: 0.068
-
Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol. 2015 Nov; 125(2):401-10.
Score: 0.060
-
Wound healing complications in brain tumor patients on Bevacizumab. J Neurooncol. 2015 Sep; 124(3):501-6.
Score: 0.060
-
Venous thromboembolism (VTE) and glioblastoma. J Neurooncol. 2015 Aug; 124(1):87-94.
Score: 0.059
-
Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol. 2014 Aug; 119(1):135-40.
Score: 0.055